Skip to main
ALT
ALT logo

Altimmune (ALT) Stock Forecast & Price Target

Altimmune (ALT) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 31%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Altimmune Inc. is positioned positively due to its promising product candidate, pemvidutide, which has demonstrated significant efficacy in reducing liver fat and improving key biomarkers associated with metabolic diseases, particularly in the treatment of obesity and metabolic-associated steatohepatitis (MASH). The product's favorable tolerability profile, coupled with its unique dual mechanism of action, enhances its potential to address not only hepatic inflammation but also systemic metabolic dysfunction, giving it a competitive edge in the biopharmaceutical market. Additionally, the FDA's willingness to consider non-invasive endpoints for conditions like alcoholic liver disease (ALD) may expedite regulatory approval, further strengthening the company's outlook.

Bears say

Altimmune has reported a significant net loss of $23.2 million in the fourth quarter of 2024, highlighting ongoing financial challenges as the company invests in the clinical development of pemvidutide. The current market landscape shows poor adoption of existing therapies, indicating potential compliance issues and skepticism regarding the effectiveness of treatments like pemvidutide, despite some weight loss results. Additionally, numerous risks associated with clinical development, competition, commercialization, and external factors compound the concerns surrounding the company's future financial performance.

Altimmune (ALT) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 31% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Altimmune (ALT) Forecast

Analysts have given Altimmune (ALT) a Buy based on their latest research and market trends.

According to 13 analysts, Altimmune (ALT) has a Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Altimmune (ALT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.